 |
Top 29 Asthma treatment startups
Oct 11, 2024 | By Jason Kwon | 24 |
These startups develop new diagnostics and treatment technologies for Asthma, like gene therapy, AI imaging analyses, new spirometers, sensors, drugs and drug-delivery solutions...
1
Country: USA | Funding: $207M
Triveni Bio focuses on the identification of novel disease by combining human genetics and precision medicine.
Triveni Bio focuses on the identification of novel disease by combining human genetics and precision medicine.
2
Country: New Zealand | Funding: $15.4M
Adherium provides digital health solutions for respiratory conditions including asthma and COPD.
Adherium provides digital health solutions for respiratory conditions including asthma and COPD.
3
Country: USA | Funding: $250M
Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.
Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.
4
Country: China | Funding: $195M
Connect Biopharmaceuticals is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation.
Connect Biopharmaceuticals is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation.
5
Country: USA | Funding: $160M
Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases, such as uncontrolled asthma, and a half-life-optimized Anticalin protein to treat anemia.
Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases, such as uncontrolled asthma, and a half-life-optimized Anticalin protein to treat anemia.
6
Country: UK
A drug discovery and development company focused on advancing novel approaches for severe respiratory conditions
A drug discovery and development company focused on advancing novel approaches for severe respiratory conditions
7
Country: USA | Funding: $85.9M
AnaptysBio is a therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease.
AnaptysBio is a therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease.
8
Country: UK | Funding: £68.8M
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
9
Country: USA | Funding: $41M
We create breath-based diagnostic and monitoring devices with the aim to improve the lives of those with respiratory conditions like asthma, COPD, cystic fibrosis and pulmonary hypertension.
We create breath-based diagnostic and monitoring devices with the aim to improve the lives of those with respiratory conditions like asthma, COPD, cystic fibrosis and pulmonary hypertension.
10
Country: USA | Funding: $33.2M
VIDA is a leader in quantitative lung analysis for COPD, emphysema and asthma, establishing objective, reproducible and quantitative
VIDA is a leader in quantitative lung analysis for COPD, emphysema and asthma, establishing objective, reproducible and quantitative
